![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer Reveals Positive Data on Trumenba Vaccine
Pfizer Reveals Positive Data on Trumenba Vaccine
May 19, 2016
Pfizer showed positive results from two Phase 3 studies demonstrating the immunogenicity of a Trumenba against invasive meningococcal B strains in the U.S. and Europe.
According to the drugmaker, the two studies — one in adolescents and one in young adults — met all primary immunogenicity endpoints. Additionally, secondary data show the vaccine demonstrated similar immune responses against 10 additional meningococcal B strains in both groups.
The results were presented at the 34th Annual Meeting of the European Society for Pediatric Infectious Diseases in Brighton, UK.
Upcoming Events
-
21Oct